Elsiglutide

Next Previous
Drug Profile

Elsiglutide

Alternative Names: ZP 1846

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zealand Pharma
  • Developer Helsinn; Zealand Pharma
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diarrhoea

Most Recent Events

  • 12 Jun 2017 Helsinn Healthcare returns its worldwide licensing rights to elsiglutide to Zealand Pharma
  • 02 Jun 2017 Preliminary adverse events data from a phase IIb trial in Diarrhoea presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Feb 2016 Helsinn Healthcare completes a phase IIb trial in Diarrhoea (Chemotherapy-induced, Prevention) in Hungary, Germany, the Czech Republic, Russia, Bulgaria, Belarus, Poland and Ukraine (SC) (NCT02383810)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top